Stay updated on Immunotherapy+IRE in Pancreatic Adenocarcinoma Clinical Trial
Sign up to get notified when there's something new on the Immunotherapy+IRE in Pancreatic Adenocarcinoma Clinical Trial page.

Latest updates to the Immunotherapy+IRE in Pancreatic Adenocarcinoma Clinical Trial page
- Check3 days agoChange DetectedThe web page has been updated to reflect a new version, changing from Revision v2.15.2 to v2.16.0.SummaryDifference0.4%
- Check10 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check40 days agoChange DetectedThe page has been updated to reflect a new version of a clinical study on pancreatic adenocarcinoma, with significant changes in the study's description and criteria for participation. The principal investigator's name remains the same, but some details about the study's methodology and inclusion/exclusion criteria have been removed.SummaryDifference16%
- Check47 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to February 25, 2025.SummaryDifference0.4%
- Check83 days agoChange DetectedThe webpage has updated its dates, removing older ones and adding new ones for 2025, along with a new plan regarding Individual Participant Data (IPD).SummaryDifference3%
- Check90 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
Stay in the know with updates to Immunotherapy+IRE in Pancreatic Adenocarcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Immunotherapy+IRE in Pancreatic Adenocarcinoma Clinical Trial page.